{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T16:44:50Z","timestamp":1789231490920,"version":"build-2803163510"},"reference-count":14,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Ceftazidime-avibactam administered at 1.25 g every 8 h was used to treat multidrug-resistant\n            <jats:named-content content-type=\"genus-species\">Pseudomonas aeruginosa<\/jats:named-content>\n            bacteremia in a critically ill patient on continuous venovenous hemofiltration (CVVH). Prefiltration plasma drug concentrations of ceftazidime and avibactam were measured at 0, 1, 2, 4, 6, and 8 h along with postfiltration and ultrafiltrate concentrations at h 2 and h 6. Plasma pharmacokinetic parameters of ceftazidime and avibactam, respectively, were as follows: maximum plasma concentration (\n            <jats:italic>C<\/jats:italic>\n            <jats:sub>max<\/jats:sub>\n            ), 61.10 and 14.54 mg\/liter; minimum plasma concentration (\n            <jats:italic>C<\/jats:italic>\n            <jats:sub>min<\/jats:sub>\n            ), 31.96 and 8.45 mg\/liter; half-life (\n            <jats:italic>t<\/jats:italic>\n            <jats:sub>1\/2<\/jats:sub>\n            ), 6.07 and 6.78 h; apparent volume of distribution at the steady state (\n            <jats:italic>V<\/jats:italic>\n            <jats:sub>ss<\/jats:sub>\n            ), 27.23 and 30.81 liters; total clearance at the steady state (CL\n            <jats:sub>ss<\/jats:sub>\n            ), 2.87 and 2.95 liters\/h; area under the concentration-time curve from 0 to 8 h (AUC\n            <jats:sub>0\u20138<\/jats:sub>\n            ), 347.87 and 85.69 mg \u00b7 h\/liter. Concentrations of ceftazidime in plasma exceeded the ceftazidime-avibactam MIC (6 mg\/liter) throughout the 8-h dosing interval. Mean CVVH extraction ratios for ceftazidime and avibactam were 14.44% and 11.53%, respectively, and mean sieving coefficients were 0.96 and 0.93, respectively. The calculated mean clearance of ceftazidime by CVVH was 1.64 liters\/h and for avibactam was 1.59 liters\/h, representing 57.1% of the total clearance of ceftazidime and 54.3% of the total clearance of avibactam. Further data that include multiple patients and dialysis modes are needed to verify the optimal ceftazidime-avibactam dosing strategy during critical illness and CVVH.\n          <\/jats:p>","DOI":"10.1128\/aac.00464-17","type":"journal-article","created":{"date-parts":[[2017,4,18]],"date-time":"2017-04-18T00:55:21Z","timestamp":1492476921000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":41,"title":["Pharmacokinetics and Dialytic Clearance of Ceftazidime-Avibactam in a Critically Ill Patient on Continuous Venovenous Hemofiltration"],"prefix":"10.1128","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3914-8400","authenticated-orcid":false,"given":"Eric","family":"Wenzler","sequence":"first","affiliation":[{"name":"University of Illinois at Chicago, College of Pharmacy, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen L.","family":"Bunnell","sequence":"additional","affiliation":[{"name":"University of Illinois at Chicago, College of Pharmacy, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan C.","family":"Bleasdale","sequence":"additional","affiliation":[{"name":"University of Illinois at Chicago, College of Medicine, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Benken","sequence":"additional","affiliation":[{"name":"University of Illinois at Chicago, College of Pharmacy, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry H.","family":"Danziger","sequence":"additional","affiliation":[{"name":"University of Illinois at Chicago, College of Pharmacy, Chicago, Illinois, USA"},{"name":"University of Illinois at Chicago, College of Medicine, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith A.","family":"Rodvold","sequence":"additional","affiliation":[{"name":"University of Illinois at Chicago, College of Pharmacy, Chicago, Illinois, USA"},{"name":"University of Illinois at Chicago, College of Medicine, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1622"},{"key":"e_1_3_2_3_2","unstructured":". September2015. Avycaz (ceftazidime\/avibactam) prescribing information. Actavis Inc. http:\/\/pi.actavis.com\/data_stream.asp?product_group=1957&p=pi&language=E. Accessed 14 September 2015."},{"key":"e_1_3_2_4_2","unstructured":". 5December2014. Food and Drug Administration Anti-Infective Drugs Advisory Committee Meeting. Ceftazidime-avibactam for injection for treatment of complicated intra-abdominal infection (used in combination with metronidazole) complicated urinary tract infection including acute pyelonephritis and limited use indication: aerobic Gram-negative infections with limited treatment options. http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/Anti-InfectiveDrugsAdvisoryCommittee\/UCM425459.pdf. Accessed 25 August 2016."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02097-16"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2016.11.005"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01964-16"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-015-0283-9"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1159\/000100864"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/49.1.129"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1086\/510079"},{"key":"e_1_3_2_12_2","first-page":"307","article-title":"Drug removal during continuous arteriovenous hemofiltration: theory and clinical observations","volume":"8","author":"Golper TA","year":"1985","unstructured":"Golper TA WedelSK KaplanAA SaadAM DontaST PaganiniEP. 1985. Drug removal during continuous arteriovenous hemofiltration: theory and clinical observations. Int J Artif Organs8:307\u2013312.","journal-title":"Int J Artif Organs"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200746120-00003"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00080-14"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01269-15"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00464-17","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00464-17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:03:35Z","timestamp":1645477415000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00464-17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":14,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["10.1128\/AAC.00464-17"],"URL":"https:\/\/doi.org\/10.1128\/aac.00464-17","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"2017-03-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-04-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-06-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00464-17"}}